Aptagen, LLC
F5R2 (ID# 9577)
DNA
Alpha-syncuclein
Protein
3.07 nM (reported value)
binding and washing buffer (10 mM Tris-HCI, 1 mM EDTA,
2 M NaCI, pH7.5)
25°C
N/A
dCpdGpdApdGpdTpdGpdGpdApdCpdGpdApdGpdTpdGpdCpdCpdTpdCpdCpdGpdGpdTpdApdCpdGpdApdGpdCpdTpdGpdTpdCpdTpdGpdApdTpdGpdGpdGpdTpdTpdTpdGpdCpdGpdCpdGpdCpdApdGpdGpdApdTpdCpdCpdAp-3'
58 nucleotides
17986.6 g/mole
552200 L/(mole·cm)
Note: Information on this aptamer oligo was obtained from the literature and hasn't been validated by Aptagen.
Zheng Y, J Qu, F Xue, Y Zheng, B Yang, Y Chang, H Yang and J Zhang. (2018). Novel DNA aptamers for Parkinson’s disease treatment inhibit a-synuclein aggregation and facilitate its degradation. Mol Ther Nucleic Acids 11:228–242.
Have your aptamer oligo synthesized ORDER
We are always looking for ways to improve. Please tell us what you think.